Cushing’s Syndrome secondary to ACTH-producing prostate adenocarcinoma: A case report

Dr M Scopazzini, Dr J Pomroy & Dr E Hatfield

Division of Diabetes, Endocrinology & Metabolic Medicine, Charing Cross Hospital
Imperial College Healthcare NHS Trust, UK

email: m scopazzini@doctors.org.uk; e hatfield@imperial.ac.uk

Introduction

Cushing’s Syndrome refers to the clinical manifestations that result from excess levels of circulating steroid. Ectopic secretion of ACTH accounts for about 10% of cases of endogenous hypercortisolaemia, and it has been found that 20% of such cases are associated with prostatic adenocarcinoma with neuroendocrine differentiation. We present a case of Cushing’s Syndrome secondary to ACTH production by prostatic adenocarcinoma.

Case Report

- 62-year-old male presenting with a two-week history of intermittent confusion, plethora and left arm weakness on a background of rapidly progressing metastatic prostate adenocarcinoma diagnosed eight months earlier. Poor response to conventional prostate cancer chemotherapy (Bicalutamide → anti-androgen (LHRH) → Docetaxel):
  - Histology report (Aug 2015) described a Gleason 5+4 adenocarcinoma with neuroendocrine differentiation;
  - Referred to the admitting medical team with a history of fast AF, new hyperglycaemia and hypokalaemia refractory to intravenous potassium replacement – initial K 2.1;
  - Managed as Cushing’s Syndrome based on excessive random cortisol and ACTH, which did not suppress following overnight dexamethasone suppression test;
  - Metyrapone + Ketoconazole initiated within 48 hours of presentation.

Investigation and management

Initial investigations: ECG – prolonged QT (550ms); BM – 17.1 (previously non-diabetic); MRI spine – malignant root compression of C6 nerve root.

Initial management: Aggressive potassium and magnesium replacement; Metyrapone and Ketoconazole started to treat hypercortisolaemia; anti-diabetic medications initiated; urgent oncology review and discussion at neuroendocrine MDTs for further management.

Cortisol, ACTH and K levels

PSA levels – ng/ml

Histology

Outcome

Once we introduced Metyrapone and Ketoconazole, our patient’s cortisol was successfully suppressed – his potassium normalised, and his hyperglycaemia was brought under control.

We reviewed his histology, which was negative for retrospective ACTH staining. We were not biopsied again. We discuss his management extensively at neuroendocrine, oncology and endocrine surgery MDTs: he was not felt to be a candidate for surgical intervention. His chemotherapy was subsequently changed from conventional prostate cancer chemotherapy to Etoposide-Carboplatin; now in his sixth cycle, he continues to show a sustained partial response – his ACTH and PSA are suppressed and his spinal metastases have regressed.

The prolonged elevation of ACTH and associated high cortisols suppressed his HPA axis, and he now requires replacement hydrocortisone.

Discussion

To our knowledge, we present the first case of Cushing’s Syndrome resulting from ectopic ACTH production arising from a prostatic adenocarcinoma with neuroendocrine differentiation. Whilst definitive management of Cushing’s Syndrome secondary to ectopic ACTH production is surgical, our patient was successfully managed on medical therapy and then chemotherapy. Crucial to his successful management was the immediate recognition of rapidly progressing hypercortisolaemia. In addition, the retrospective review of history and subsequent effective MDT discussion enabled his oncology team to review his initial diagnosis and alter his chemotherapy regimen accordingly.

References